Michael J. Farrell - 17 Jan 2023 Form 4 Insider Report for RESMED INC (RMD)

Role
Chief Executive Officer
Signature
Michael J. Farrell, Chief Executive Officer
Issuer symbol
RMD
Transactions as of
17 Jan 2023
Transactions value $
-$945,481
Form type
4
Filing time
18 Jan 2023, 15:28:32 UTC
Previous filing
04 Jan 2023
Next filing
16 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RMD ResMed Common Stock Options Exercise $328K +5.68K +1.3% $57.76 443K 17 Jan 2023 Direct F1
transaction RMD ResMed Common Stock Sale -$1.27M -5.68K -1.28% $224.36 437K 17 Jan 2023 Direct F1, F2
holding RMD ResMed Common Stock 4.09K 17 Jan 2023 Lisette and Michael Farrell Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RMD ResMed Common Stock Options Options Exercise $0 -5.68K -8.61% $0.00 60.2K 17 Jan 2023 ResMed Common Stock 5.68K $57.76 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction was conducted under a Rule 10b5-1 plan.
F2 This transaction was executed in multiple trades at prices ranging from $220.59 - $225.635. The price reported above reflects the weighted average sale price.
F3 Represents date options first became exercisable. Options vest 1/3 per year.